Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- MTPC Files for Expanded Combination-Use Indication for DPP-4 Inhibitor Tenelia
February 28, 2013
- GSK Launches Anti-Malaria Drug Malarone in Japan
February 27, 2013
- Takeda Recalling Renal Anemia Drug Omontys in US after Death Reports
February 26, 2013
- Combined Sales of Januvia and Glactiv Break 110 Billion Yen in 2012: IMS Japan
February 26, 2013
- Janssen Files World’s 1st Application for Hepatitis C Treatment Simeprevir in Japan
February 26, 2013
- 3-Drug H. pylori Eradication Therapy Receives Additional Indication for H. pylori Gastritis
February 25, 2013
- Zeria to Launch Hypophosphatemia Treatment Phosribbon Combination Granules on March 4
February 25, 2013
- MTPC Calls for Proper Use of Telavic Following Reports of Serious Infections
February 25, 2013
- LEO Pharma of Denmark to Fully Enter Psoriasis Market in Japan in 2014
February 22, 2013
- Lotriga, Equa, Aimix Most Promoted Products in GP, HP Markets in January: Rep Track Survey
February 22, 2013
- Astellas Files for Additional Indication for Dormicum Based on Data from Public Domain
February 22, 2013
- Shionogi Settles Lawsuit over Royalties Payment with US Firm InterMune
February 22, 2013
- Shire Appoints Steve Engen as Representative Director of Japanese Subsidiary
February 22, 2013
- Actelion Receives Approval for Generic Version of Flolan
February 22, 2013
- Chugai Sues 4 Companies Including Iwaki Seiyaku for Patent Infringement Related to Oxarol Ointment
February 21, 2013
- HIV Treatment Dolutegravir Gets FDA Priority Review: ViiV Healthcare
February 21, 2013
- Radium-223 Granted Priority Review Status by US FDA: Bayer HealthCare
February 19, 2013
- DSP Targets Sales of 450 Billion Yen in FY2017 by Making Latuda Blockbuster
February 19, 2013
- Blopress Retakes Top Spot in Domestic Ethical Drug Market in 2012: IMS Japan
February 19, 2013
- Kowa Says Listing Application for Livalo Generic “Won’t Be Filed”; Possibility Nixed for 1st AG in Japan
February 18, 2013
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…